Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
AKYA Akoya Biosciences Inc
- Stocks
- Healthcare
- NASDAQ: AKYA
Price (delayed)
$0.9457
Market cap
$47.17M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.96
Enterprise value
$109.85M
As The Spatial Biology Company®, Akoya Biosciences’ mission is to bring context to the world of biology and human health through the power of spatial phenotyping. The company offers comprehensive
Highlights
Akoya Biosciences's EPS has increased by 34% YoY and by 14% from the previous quarter
Akoya Biosciences's net income has increased by 30% YoY and by 14% QoQ
The gross profit has declined by 6% year-on-year but it has increased by 3.1% since the previous quarter
The equity has dropped by 178% since the previous quarter and by 118% year-on-year
The company's quick ratio has shrunk by 84% YoY and by 78% QoQ
Key stats
What are the main financial stats of AKYA
Market
Valuations
Earnings
Shares outstanding
49.88M
Market cap
$47.17M
Enterprise value
$109.85M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.37
Revenue
$79.96M
Gross profit
$49.37M
Operating income
-$39.1M
Net income
-$47.53M
EBIT
-$37.09M
EBITDA
-$29.69M
Free cash flow
-$32.34M
Per share
Balance sheet
Liquidity
EPS
-$0.96
EPS diluted
-$0.96
Free cash flow per share
-$0.65
Book value per share
-$0.12
Revenue per share
$1.61
TBVPS
$1.62
Total assets
$112.65M
Total liabilities
$118.54M
Debt
$83.72M
Equity
-$5.89M
Working capital
-$41.87M
Debt to equity
-14.22
Current ratio
0.61
Quick ratio
0.37
Net debt/EBITDA
-2.11
Margins
Efficiency
Dividend
EBITDA margin
-37.1%
Gross margin
61.7%
Net margin
-59.4%
Operating margin
-48.9%
Return on assets
-37.2%
Return on equity
-505.8%
Return on invested capital
-32.1%
Return on capital employed
-812.2%
Return on sales
-46.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
AKYA stock price
How has the Akoya Biosciences stock price performed over time
Intraday
-6.83%
1 week
-15.94%
1 month
-24.34%
1 year
-67.39%
YTD
-58.7%
QTD
-31.96%
Financial performance
How have Akoya Biosciences's revenue and profit performed over time
Revenue
$79.96M
Gross profit
$49.37M
Operating income
-$39.1M
Net income
-$47.53M
Gross margin
61.7%
Net margin
-59.4%
The company's operating income rose by 35% YoY and by 17% QoQ
Akoya Biosciences's net income has increased by 30% YoY and by 14% QoQ
Akoya Biosciences's operating margin has increased by 24% YoY and by 15% from the previous quarter
The net margin has grown by 18% YoY and by 12% from the previous quarter
Price vs fundamentals
How does AKYA's price correlate with its fundamentals
Growth
What is Akoya Biosciences's growth rate over time
Valuation
What is Akoya Biosciences stock price valuation
P/E
N/A
P/B
N/A
P/S
0.59
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
1.37
Akoya Biosciences's EPS has increased by 34% YoY and by 14% from the previous quarter
The equity has dropped by 178% since the previous quarter and by 118% year-on-year
The price to sales (P/S) is 87% lower than the 5-year quarterly average of 4.7 and 55% lower than the last 4 quarters average of 1.3
The revenue has decreased by 15% YoY and by 2.1% QoQ
Efficiency
How efficient is Akoya Biosciences business performance
The ROE has plunged by 74% from the previous quarter
The return on invested capital is up by 36% year-on-year but it has declined by 4.6% since the previous quarter
Akoya Biosciences's ROS has increased by 26% YoY and by 15% from the previous quarter
Akoya Biosciences's return on assets has increased by 7% QoQ and by 4.1% YoY
Dividends
What is AKYA's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for AKYA.
Financial health
How did Akoya Biosciences financials performed over time
AKYA's total assets is 5% smaller than its total liabilities
The company's quick ratio has shrunk by 84% YoY and by 78% QoQ
Akoya Biosciences's current ratio has shrunk by 80% YoY and by 77% QoQ
The equity has dropped by 178% since the previous quarter and by 118% year-on-year
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.